Comparison of 30 mCi and 50 mCi I-131 doses for ablation of thyroid remnant in papillary thyroid cancer patients

被引:3
|
作者
Cai, Xiao Yue [1 ]
Vijayaratnam, Niranjan [1 ]
McEwan, Alexander J. B. [2 ]
Reif, Rebecca [2 ]
Morrish, Donald W. [1 ]
机构
[1] Univ Alberta, Dept Med, 9-114 Clin Sci Bldg, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
关键词
30; mCi; 50; differentiated thyroid cancer; radioactive iodine ablation; RADIOIODINE; SURVIVAL; OUTCOMES; THERAPY; DEATH;
D O I
10.1080/07435800.2017.1346662
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of the study: To compare efficacy of thyroid remnant ablation using 30mCi or 50 mCi 131-I in papillary thyroid cancer patients. Materials and methods: Five hundred and fifteen consecutive patients with Tumor-Node-Metastasis (TNM) stages T1-T3 N1/N0/NX receiving either 30 mCi or 50 mCi I-131 were analyzed for the effectiveness of remnant ablation using rhTSH-stimulated serum thyroglobulin. One hundred and five consecutive patients receiving 100 mCi I-131 were analyzed for the incidence of radiation thyroiditis and sialadenitis. Results and conclusions: Doses of 30 mCi and 50 mCi were equally effective for low-and moderate-risk disease but 30 mCi was less effective for T1T2NX disease, and 50 mCi was less effective for T3 compared to T1T2 disease. Low dose radiation hypersensitivity or unknown more extensive disease may have accounted for observed differences. Radiation thyroiditis and sialadenitis were more common in a comparison series of 100 mCi dose compared to 30 mCi, but not more common than in 50 mCi doses.
引用
收藏
页码:11 / 14
页数:4
相关论文
共 50 条
  • [1] Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes
    Kukulska, Aleksandra
    Krajewska, Jolanta
    Gawkowska, Marzena
    Paliczka-Cieslik, Ewa
    Handkiewicz-Junak, Daria
    Kropinska, Aleksandra
    Puch, Zbigniew
    Olczyk, Tomasz
    Roskosz, Jozef
    Jarzab, Barbara
    ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (05) : 1241 - 1247
  • [2] Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients
    Kaewput, Chalermrat
    Pusuwan, Pawana
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2021, 20 (01) : 54 - 60
  • [3] Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
    Prpic, Marin
    Dabelic, Nina
    Stanicic, Josip
    Jukic, Tomislav
    Milosevic, Milan
    Kusic, Zvonko
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (09) : 744 - 751
  • [4] Ablation of the Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: A Meta-Analysis Revisited
    Doi, Suhail A. R.
    Woodhouse, Nicholas J.
    Thalib, Lukman
    Onitilo, Adedayo
    CLINICAL MEDICINE & RESEARCH, 2007, 5 (02) : 87 - 90
  • [5] Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer
    Uno, Atsuhiko
    Takeda, Hiroki
    Mori, Masashi
    Yamamoto, Yoshifumi
    Takenaka, Yukinori
    Enomoto, Keisuke
    Takeda, Noriaki
    JOURNAL OF MEDICAL INVESTIGATION, 2023, 70 (1-2) : 17 - 21
  • [6] Comparable Ablation Efficiency of 30 and 100 mCi of I-131 in Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria
    Zaman, M. U.
    Fa, N.
    Zaman, A.
    Zaman, U.
    Tahseen, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S372 - S373
  • [7] Comparison of efficacy of 2 220 MBq versus 3 700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer
    Fish, S. A.
    Basu, S.
    Alavi, A.
    Mandel, S. J.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (05) : 560 - 563
  • [8] I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
    Lin, Rong
    Banafea, Omar
    Ye, Jin
    BMC GASTROENTEROLOGY, 2015, 15
  • [9] Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine
    Kuna, Sanja Kusacic
    Samardzic, Tatjana
    Tesic, Vanja
    Medvedec, Mario
    Kuna, Krunoslav
    Bracic, Irena
    Despot, Marija
    Dodig, Damir
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (04) : 263 - 269
  • [10] TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer
    Ju, Nianting
    Hou, Liying
    Song, Hongjun
    Qiu, Zhongling
    Wang, Yang
    Sun, Zhenkui
    Luo, Quanyong
    Shen, Chentian
    EUROPEAN THYROID JOURNAL, 2023, 12 (04)